AbbVie (ABBV) and West Pharmaceutical (WST) announced a definitive agreement for AbbVie to acquire a device manufacturing facility in Tempe, Arizona and associated intellectual property from West. The acquisition of the manufacturing site will expand AbbVie’s drug delivery device manufacturing capabilities and capacity. AbbVie plans to hire approximately 200 employees at the site and invest more than $175M to acquire, as well as modernize and fully integrate it into its global manufacturing network. The transaction includes the transfer of manufacturing facilities, including multiple production lines, and 3.5 mL on-body injector technology to support production of current and next-generation AbbVie immunology and neuroscience medicines. The transaction is anticipated to close in mid-2026, subject to closing conditions.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Tempus AI (TEM) Tops $1.1B in Total Contract Value as Pharma Demand for AI Tools Surges
- The Week That Was, The Week Ahead: Macro and Markets, Jan. 11
- AbbVie’s ABBV-243 Phase 1 Trial: What Early Safety Work Means for Long-Term Investors
- Revolution Medicines price target raised to $147 from $80 at Wedbush
- M&A News: Revolution Medicines (RVMD) Stock Rallies on News of Potential Acquisition by Merck